Skip to main content

Advertisement

Log in

Cancer immunotherapy: breaking the barriers to harvest the crop

  • Commentary
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Multiple points of intervention to engender successful cancer immunotherapy.
Figure 2: Potential pathways by which the NCI and FCA could facilitate the development of combinatorial immunotherapies.

References

  1. Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    Article  CAS  Google Scholar 

  2. Akhtar, S. & Maghfoor, I. N. Engl. J. Med. 346, 1830–1831 (2002).

    Article  Google Scholar 

  3. Winter, G. & Harris, W.J. Trends Pharmacol. Sci. 14, 139–143 (2003).

    Article  Google Scholar 

  4. Willett, C.G. et al. Nat Med. 10, 145–147 (2004).

    Article  CAS  Google Scholar 

  5. Waldmann, H. Med. Oncol. 19 (Suppl.), S3–S9 (2002).

    Article  Google Scholar 

  6. Hersey, P. Intern. Med. J. 33, 33–43 (2003).

    Article  CAS  Google Scholar 

  7. Yee, C. et al. Proc. Natl. Acad. Sci. USA 99, 16168–16173 (2002).

    Article  CAS  Google Scholar 

  8. Dudley, M.E. et al. Science 298, 850–854 (2002).

    Article  CAS  Google Scholar 

  9. Pardoll, D.M. Nat. Rev. Immunol. 2, 227–238 (2002).

    Article  CAS  Google Scholar 

  10. Blattman, J.N. & Greenberg, P.D. Science 305, 200–205 (2004).

    Article  CAS  Google Scholar 

  11. Levitsky, H.I. Cancer J. 6 (Suppl.), S281–S290 (2000).

    PubMed  Google Scholar 

  12. Pardoll, D. Annu. Rev. Immunol. 21, 807–839 (2003).

    Article  CAS  Google Scholar 

  13. Chambers, C.A., Kuhns, M.S., Egen, J.G. & Allison, J.P. Annu. Rev. Immunol. 19, 565–594 (2001).

    Article  CAS  Google Scholar 

  14. Dong, H. et al. Nat. Med. 8, 793–800 (2002).

    Article  CAS  Google Scholar 

  15. Sutmuller, R.P. et al. J. Exp. Med. 194, 823–832 (2001).

    Article  CAS  Google Scholar 

  16. Phan, G.Q. et al. Proc. Natl. Acad. Sci. USA 100, 8372–8377 (2003).

    Article  CAS  Google Scholar 

  17. Stolberg, S.G. New York Times Magazine 28 Nov (1999) pp. 136–140, 149–150.

    Google Scholar 

  18. Smith, L. & Byers, J.F. JONAS Healthc Law Ethics Regul. 4, 104–110 (2002).

    Article  Google Scholar 

  19. Grilley, B.J. & Gee, A.P. Cytotherapy 5, 197–207 (2003).

    Article  CAS  Google Scholar 

  20. Ergenzinger, E. & Spruill, M. Scientist 17, 43 (2003).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pardoll, D., Allison, J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10, 887–892 (2004). https://doi.org/10.1038/nm0904-887

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0904-887

  • Springer Nature America, Inc.

This article is cited by

Navigation